Received: 11 February 2022
Accepted: 14 June 2022
First Online: 26 July 2022
: The CAPRISA 002 study was reviewed and approved by the University of KwaZulu-Natal Biomedical Research Ethics Committee (E013/04). All methods were carried out in accordance with relevant guidelines and regulations. All study participants provided written informed consent at study entry.
: Not applicable.
: The authors declare that they have no competing interests. AN is supported by National Institutes of Health (NIH) grants K43TW011437 and 1R01 AI152142-01.